Credit Suisse Starts Sarepta Therapeutic (SRPT) at Outperform

October 18, 2016 6:34 AM EDT
Get Alerts SRPT Hot Sheet
Price: $36.49 -3.54%

Rating Summary:
    17 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 35 | Down: 31 | New: 9
Trade SRPT Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Credit Suisse initiates coverage on Sarepta Therapeutic (NASDAQ: SRPT) with a Outperform rating and a price target of $68.00.

Analyst Alethia Young commented, "Sarepta is an RNA-based therapeutics company currently focused on drug development in Duchenne Muscular Dystrophy (DMD). Sarepta received accelerated approval for its first drug in DMD called EXONDYS 51 to treat patients with a certain mutation that is about 13% of the total DMD patient population. The drug launch is currently underway and we estimate first sales in 4Q16. We are positive on Sarepta owing to (1) our positive expectation on the US EXONDYS 51 launch, (2) confidence of approval and IP settlement in Europe, and (3) early success with the Exon 53 program in mid-2017 (which could add another 8% of patients). Ultimately, this platform could treat up to 80% of patients with DMD if successful clinically."

The firm models US EXONDYS 51 Sales of ~$400M by 2020, they think ultimately US payers will support reimbursement.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $48.94 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Credit Suisse

Add Your Comment